BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25635965)

  • 1. Visual inspection after acetic acid (VIA) is highly heterogeneous in primary cervical screening in Amazonian Peru.
    Almonte M; Ferreccio C; Luciani S; Gonzales M; Delgado JM; Santos C; Alvarez M; Cuzick J; Sasieni P
    PLoS One; 2015; 10(1):e0115355. PubMed ID: 25635965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of conventional pap smear, liquid-based cytology, visual inspection and human papillomavirus testing as optional screening tools among latin american women <35 and > or =35 years of age: experience from the Latin American Screening Study.
    Syrjänen K; Derchain S; Roteli-Martins C; Longatto-Filho A; Hammes LS; Sarian L;
    Acta Cytol; 2008; 52(6):641-53. PubMed ID: 19068666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytology versus HPV testing for cervical cancer screening in the general population.
    Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
    Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology.
    Longatto-Filho A; Naud P; Derchain SF; Roteli-Martins C; Tatti S; Hammes LS; Sarian LO; Eržen M; Branca M; de Matos JC; Gontijo R; Maeda MY; Lima T; Costa S; Syrjänen S; Syrjänen K
    Virchows Arch; 2012 Jun; 460(6):577-85. PubMed ID: 22562132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Health technology assessment report. Use of liquid-based cytology for cervical cancer precursors screening].
    Ronco G; Confortini M; Maccallini V; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(5 Suppl 2):e1-e33. PubMed ID: 23139163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A study of cervical cancer screening algorithms].
    Zhao FH; Zhang WH; Pan QJ; Zhang X; Chen W; Liu B; Ma JF; Hu SY; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):420-4. PubMed ID: 20819481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study.
    Syrjänen K; Naud P; Derchain S; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Hammes LS; Matos J; Gontijo R; Sarian L; Braganca J; Arlindo FC; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S
    Anticancer Res; 2005; 25(5):3469-80. PubMed ID: 16101165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.
    Salmerón J; Lazcano-Ponce E; Lorincz A; Hernández M; Hernández P; Leyva A; Uribe M; Manzanares H; Antunez A; Carmona E; Ronnett BM; Sherman ME; Bishai D; Ferris D; Flores Y; Yunes E; Shah KV
    Cancer Causes Control; 2003 Aug; 14(6):505-12. PubMed ID: 12948281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
    Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
    Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
    Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
    J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
    Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
    JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cervical cancer screening in north east Thailand using the visual inspection with acetic acid (VIA) test and its relationship to high-risk human papillomavirus (HR-HPV) status.
    Ekalaksananan T; Pientong C; Thinkhamrop J; Kongyingyoes B; Evans MF; Chaiwongkot A
    J Obstet Gynaecol Res; 2010 Oct; 36(5):1037-43. PubMed ID: 20868444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Descriptive Study of Different Methods of Cervical Cancer Screening among Ever-Married Women in 35-Year and 45-Year Cohorts in Kalutara District, Sri Lanka.
    Mapitigama N; Moonesinghe LN; Punchihewa R; Perera C
    Asian Pac J Cancer Prev; 2023 May; 24(5):1487-1493. PubMed ID: 37247267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?
    Bhatla N; Dar L; Patro AR; Kumar P; Kriplani A; Gulati A; Iyer VK; Mathur SR; Sreenivas V; Shah KV; Gravitt PE
    Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear.
    Monsonego J; Bohbot JM; Pollini G; Krawec C; Vincent C; Merignargues I; Haroun F; Sednaoui P; Monfort L; Dachez R; Syrjänen K
    Gynecol Oncol; 2005 Oct; 99(1):160-8. PubMed ID: 16023184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Detection of Cervical Cancer and Precancer Through Use of Imaged Liquid-Based Cytology in Routine Cytology and HPV Cotesting.
    Austin RM; Onisko A; Zhao C
    Am J Clin Pathol; 2018 Oct; 150(5):385-392. PubMed ID: 30137189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study.
    Carter RL; Kang L; Darcy KM; Kauderer J; Liao SY; Rodgers WH; Walker JL; Lankes HA; Dunn ST; Stanbridge EJ
    Cancer Causes Control; 2012 Dec; 23(12):2013-21. PubMed ID: 23073789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.